On March 8, 2021 Cofactor Genomics, the company bridging the precision medicine gap, reported new data published in Frontiers in Oncology1 by Women & Infants Hospital of Rhode Island (Press release, Cofactor Genomics, MAR 8, 2021, View Source [SID1234576190]). The data highlight the utility of Cofactor’s Predictive Immune Modeling technology in elucidating the immune landscape of epithelial ovarian cancer (EOC) for immunotherapy development, and to identify prognostic indicators of response to frontline chemotherapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
EOC is the most lethal of all gynecological malignancies, with more than 21,000 diagnoses and almost 14,000 deaths anticipated from the disease in the United States in 2020.2 Currently, several EOC clinical trials center upon immunotherapy;3 however, while melanoma and non-small cell lung cancer (NSCLC) patients have seen a great benefit from targeting immune checkpoint inhibitors, such cytotoxic T lymphocyte-associated protein-4 (CTLA-4) or programmed cell death protein 1 (PD-1), EOC patients have only exhibited response rates of 10 to 15 percent.4 Despite these poor response rates, evidence suggests that EOC is an immunogenic cancer,5,6 and in the paper, the team led by Jennifer Ribeiro, Ph.D., at Women & Infants Hospital outlined how these results lay the foundation for the development of better immunotherapy agents.
The primary investigator on the study, Dr. Ribeiro, stated, "This study offers new insights into high grade serous ovarian cancer that have the potential to make an impact in how patients are treated in the future. Using the ImmunoPrism platform, we have shown that immunological signatures are indeed related to patient outcomes in ovarian cancer."
In the study, the authors utilized the Cofactor Genomics ImmunoPrism platform to evaluate a cohort of high grade serous ovarian cancer (HGSOC) tumors to identify an immune-related gene expression model that may serve as a prognostic indicator of response to frontline chemotherapy. They found that the immunological markers CTLA-4, LAG-3, and Treg immune cells are more abundant in HGSOC patients with longer progression-free survival (PFS). Moreover, they investigated which immunological features in a tumor led to improved outcomes, which represent opportunities for novel immunotherapeutic approaches. The study also revealed that ICOS was significantly more highly expressed in patients with longer PFS, and strongly correlated with CTLA-4, PD-1, and specific subsets of immune cell infiltration. The results from the tumor cohort were confirmed using The Cancer Genome Atlas (TCGA) ovarian cancer dataset where high ICOS and LAG-3 levels were also significantly associated with longer survival.
The study builds on Cofactor’s previously presented work using its Predictive Immune Modeling technology to identify novel immune signals in other disease indications, including sarcoma, non-small cell lung cancer (NSCLC), and recurrent and metastatic squamous cell carcinoma of the head and neck (RM-HNSCC). The company has also announced a list of disease targets for diagnostic development and is current recruiting clinical partners: View Source